Last updated: 2026-10-14 20:03:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Myriad Genetics Inc. (MYGN) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $4,14, with a market capitalisation of $401,73M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,74 to $8,59. This page covers its latest market performance, valuation, price trends and company information.
$401,73M | |
$4,08 | |
$50,44 | |
$2,74 | |
$4,08 | |
1,57M | |
2,08M | |
-- | |
$8,59 | |
$2,74 | |
-- | |
-- |
Myriad Genetics Inc. (MYGN) is trading at $4,14 in after-hours trading as of 2026-10-14 19:46:08, up 1,35% ($0,05) from the regular-session close of $4,08.
After-hours trading shows how investors are pricing MYGN after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Myriad Genetics Inc. (MYGN) moved from $4,58 to $4,14, representing a decline of 9,54% ($0,44).
The stock traded between $4,05 and $4,83 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,79 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 24,0%
MYGN is currently trading at $4,14, placing it 24,0% of the way from its 52-week low of $2,74 to its 52-week high of $8,59. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 2700 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Myriad Genetics Inc. (MYGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.